Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

Revenio Group

17.00 EUR

-4.92 %

14,292 following
Corporate customer

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-4.92 %
-3.63 %
-23.77 %
-24.11 %
-27.66 %
-31.03 %
-57.65 %
-69.86 %
+794.74 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
453.58M EUR
Turnover
2.42M EUR
P/E (adj.) (26e)
19.17
EV/EBIT (adj.) (26e)
14.11
P/B (26e)
3.56
EV/S (26e)
3.5
Dividend yield-% (26e)
2.94 %
Coverage
Recommendation
Buy
Target price
24.00 EUR
Updated
12.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 12.02.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.4
2026

Interim report Q1'26

6.8
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press releaseyesterday

Notice to the Annual General Meeting of Revenio Group Corporation

Revenio Group
Visionix complements Revenio's vision – clear strategy, valuable framework
Analyst Comment4/14/2026, 8:57 AM by
Juha Kinnunen

Visionix complements Revenio's vision – clear strategy, valuable framework

The Visionix acquisition gives Revenio immediate access to the growing OCT market, but it also brought much more.

Revenio Group
Revenio’s press conference on the Visionix acquisition
Webcast4/13/2026, 11:00 AM

Revenio’s press conference on the Visionix acquisition

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release4/13/2026, 6:45 AM

Revenio to arrange a press conference on the Visionix acquisition today April 13, 2026 at 2.00 p.m.

Revenio Group
Regulatory press release4/13/2026, 6:32 AM

Revenio Group Corporation cancels its Annual General Meeting 2026 and moves it to a later date

Revenio Group
Regulatory press release4/13/2026, 6:30 AM

Inside information: Revenio accelerates growth and value creation by acquiring Visionix, becoming a leading turnkey solutions provider in the global eye care market

Revenio Group
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release3/23/2026, 9:30 AM

Revenio Group Corporation: Notice to the Annual General Meeting 2026

Revenio Group
Regulatory press release3/23/2026, 9:00 AM

Revenio Group Corporation’s Annual reporting package 2025 has been published

Revenio Group
Regulatory press release3/17/2026, 2:00 PM

Change in the amount of Revenio Group Corporation’s treasury shares

Revenio Group
Regulatory press release3/12/2026, 2:00 PM

Revenio Group Corporation appoints Juha Jaatinen as Interim Chief Financial Officer

Revenio Group
Regulatory press release2/18/2026, 12:00 PM

The realization of Revenio Group Corporation’s share plan RSP 2024-2026 for the year 2025

Revenio Group
Press release2/12/2026, 8:15 AM

iCare partners with Mediwhale on AI-powered cardiovascular disease prevention

Revenio Group
Revenio Q4'25: Market no longer cares about iCare
Research2/12/2026, 10:16 AM by
Juha Kinnunen

Revenio Q4'25: Market no longer cares about iCare

The stock market no longer seems to care about iCare and has relegated Revenio's stock to the discount bin. We see this as an opportunity.

Revenio Group
Revenio Financial Statement Bulletin 2025
Webcast2/11/2026, 1:00 PM

Revenio Financial Statement Bulletin 2025

Revenio Group
Regulatory press release2/11/2026, 7:00 AM

Revenio Group Corporation: Financial Statements Release January 1 – December 31, 2025

Revenio Group
Revenio Q4'25 preview: Valuation reaches historic lows
Research2/9/2026, 8:41 AM by
Juha Kinnunen

Revenio Q4'25 preview: Valuation reaches historic lows

Revenio's valuation has fallen to a historically low level, as the industry faces concerns, especially after Zeiss's grim profit warning. We consider the concerns regarding Revenio to be exaggerated and estimate the company's earnings to be firmly on an upward trend this year.

Revenio Group
Press release2/6/2026, 2:00 PM

Modular Finance IR Consensus: Revenio Group – Consensus estimates Q4 2025

Revenio Group
Press release2/5/2026, 8:30 AM

Revenio appoints Jussi Nevanlinna to lead Icare’s Global Marketing

Revenio Group
Press release1/28/2026, 7:00 AM

Revenio Group’s Financial statement release 2025 will be published on February 11, 2026

Revenio Group
Forum discussions
At least according to statistics, the French work more hours per week on average than Finns. ec.europa.eu – 30 May 24 How many hours per week do Europeans work? In 2023, the actual weekly working hours for people aged 20-64 in their main job, in the EU, averaged 36.1 hours. A closer...
yesterday
by Verneri Pulkkinen
73
France. Comfort-seeking. Croissants. Trade unions. A bottle of wine at lunch, at dinner a little more freely. Surely, in this case, too, it was necessary to promise that all employees working in France would transfer as old employees and that they would be given a 2-3 year guarantee...
4/14/2026, 3:38 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
32
I wonder if we’ll start seeing some insider buying from the executive management as well, now that great business is on the horizon and the valuation is knocking on seven-year lows. If they don’t buy now, it says a lot.
3 hours ago
by Syyntakeeton
31
I’m not a Revenio owner, but I’ve been watching the stock slide out of the corner of my eye. For the owners’ sake, I would have hoped that Reve would have been the target of the acquisition itself. I once worked with the French in an M&A situation, and I certainly don’t envy the ...
yesterday
by TitoK
28
The long-awaited acquisition, which has been hinted at for a long time. As a long-term owner of Revenio, I awaited it calmly for three reasons: Previous track record: The Centervue acquisition, as already mentioned here, was handled from start to finish as a textbook example, thoughtfully...
4/14/2026, 12:54 PM
by Iiizi
26
@Juha_Kinnunen’s thoughts on the acquisition, also in video form. Largely a repetition of the same points: In the short term, it’s a slightly expensive acquisition. If synergies are realized and cross-selling, etc., succeeds, then the multiples already look significantly more moderate...
4/14/2026, 11:52 AM
by Jackwelshh
23
I don’t own Revenio shares myself, but I’ve been following the company for a while and am somewhat familiar with the opportunities and challenges related to transformative situations like this. I can confirm the same experience, including M&A and carve-out situations. It’s one thing...
yesterday
21
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.